Lactobacillus gasseri SBT2055

Lactobacillus gasseri SBT2055 (SBT2055), which originates in Japanese adults, was identified in the 1990s while researching the Lactobacillus gasseri, which exists inside the intestines, in search of a strain with flavor characteristics and resistance to stomach acid. In 2001, it was confirmed that this strain remains in the human intestines for a long time.
Reference literature:
Fujiwara S et al., Journal of Applied Microbiology, 90,343-352, (2001)

Driven by the expected health benefits of this persistency, various research has been conducted thus far. In a study published in 2010, the first human trials conducted confirmed that SBT2055 has the effect of reducing visceral fat. It was also indicated that the mechanism of this reduction is a fat absorption suppression effect in SBT2055.
In 2015, we launched a yogurt product containing SBT2055 as a Food with Function Claims. Later in 2018, we obtained registration as a FOSHU (Food for Specified Health Uses). In 2020, we launched a supplement product containing SBT2055 as a Food with Function Claims.
In addition to visceral fat accumulation prevention, SBT2055 has also been confirmed to have other benefits, including anti-inflammatory properties against gingivitis, and infection prevention against the influenza viruses.
Reference literature:
Kadooka Y. et al. European Journal of Clinical Nutrition, 64, 636–643, (2010)
Ogawa A. et al., Lipids in Health and Disease, 14:20, (2015)
Kobayashi R. et al., Scientific Reports, 7: 545 (2017)
Nishihira J. et al., Functional Foods in Health and Disease, 6(9) 544-568, (2016)